Bowman and Brooke was recognized for the seventh time as a Law360 Product Liability Practice Group of the Year for its "versatility" and "long-established reputation as a defense leader."
Bowman and Brooke was ranked in the Nationwide Product Liability category by Chambers USA and recognized for a "[d]eep trial bench with experience trying cases across the country. " (Chambers USA 2016)
Bowman and Brooke attorneys are leaders in their fields, called upon by industry organizations and the media to provide insights on legal trends and developments.
Bowman and Brooke's Medical Device and Pharmaceutical Litigation practice includes nearly two dozen experienced trial lawyers serving as national coordinating counsel; lead trial counsel, including at bellwethers; regional; and local counsel in a wide range of cases across the country, including some of today's most high-profile mass tort litigation matters. With a passion and drive for mastering complex medical, scientific, epidemiological, engineering and regulatory issues, Bowman and Brooke's lawyers deliver legal representation that is innovative and cost-conscious.
Our experience includes developing a formidable defense strategy aligned with your business objectives; serving as national coordinating counsel to implement a unified plan with the bandwidth to deploy a team of lawyers working up multiple cases at once; preparing discovery protocols and conducting large-scale document productions; preparing company witnesses for depositions and trial testimony; assessing litigation risks and the regulatory impact of litigation; ensuring a cutting-edge and consistent legal and appellate strategy; and, of course, trying cases before juries.
Whether assessing product warnings and package inserts to meet FDA compliance; briefing and arguing appeals in federal and state courts; arguing before the JPML; arguing for early dismissals for lack of product identification; arguing legal and evidence-based motions such as preemption, Daubert-related expert challenges, the Learned Intermediary Doctrine and Iqbal/Twombly pleading challenges; opposing class certification; or heading to trial, Bowman and Brooke’s Medical Device and Pharmaceutical team has the depth and experience necessary to critically evaluate claims and aggressively defend our healthcare clients.
Because medical device and pharmaceutical product liability cases involve complex medical and scientific issues, the recruitment and development of qualified expert witnesses capable of communicating clearly to judges and juries is essential. Over the last twenty years, we have developed relationships with some of the foremost medical and scientific experts in the country in most major medical specialties. We work hand-in-hand with nationally-recognized FDA and regulatory consultants, clinical scientists, epidemiologists and warnings experts. We routinely recruit and prepare experts from coast to coast in the areas of drug safety, clinical trials, medical affairs and marketing, including sales representatives. Translating complex medical and scientific concepts to lay juries is an area in which we excel. When cases are assigned to us, we are able to immediately tap into this network of experts who have previously contributed to the resolution of our cases. We have compiled contacts for hundreds of medical experts in various fields nationwide, which are invaluable resources in our defense of cases.
Additionally, our lawyers understand the regulatory process and have supported clients with supplemental reporting following clinical trial claims, documentation for PMA and 510(k) device litigation, and with regulatory filings involving inquiries relating to possible adverse events.
To help you stay ahead, we monitor regional and national filing trends, evolving case law, medical and scientific journals, and emerging regulatory issues. We author articles and make presentations on cutting edge issues. We go beyond our medical, scientific and regulatory focus to understand your business needs and conscientiously deliver results that complement your core business objectives.
With offices strategically located around the country, our lawyers have defended thousands of cases across the United States, including coordinated proceedings in New Jersey, Pennsylvania, California, Nevada, West Virginia, New York and Florida.
In addition to our attorneys, we employ a team of highly skilled nurse paralegals who provide a unique medical review for our cases. Our team even includes a partner who boasts both a legal and nursing practice, working a shift each week as a neuroscience-unit nurse at Detroit’s William Beaumont Hospital.
The list of medical devices and pharmaceuticals we have defended is vast. A brief representative sampling of these products can be found on the previous page. We have defended several of these products in individual cases and in national coordinating counsel roles, as well as in the mass tort setting and at trial.
When your product and your name is at stake, never settle when it comes to your counsel. Insist on Bowman and Brooke.
Breg, Inc. received a decisive win on February 6, 2013 in the first bellwether case in the California infusion pump JCCP to go to trial.
On Monday, November 7, 2016, the FDA issued final guidance on Medical Device Reporting for Manufacturers. The FDA will hold a webinar on November 30, 2016 to help manufacturers understand the information provided in this final guidance document. Following a brief presentation, the FDA will also respond to participants’ questions.
San Jose Managing Partner Anne Hanna and Associate Lindsey Adams-Hess have co-authored the first part of an article series on 3D printed pharmaceuticals and devices with Berkley Life Sciences.
Part one of the series, "Assessing, Managing and Insuring Against Risk in the Next Era of Drugs and Medical Devices," delves into the liability implications and risk management of 3D printing in the life sciences industries. Cindy Khin and Sonia Weiss of Berkley Life Sciences also co-authored the article, providing their thought leadership from the insurance perspective.
The 3D printing boom in the last several years has sweeping implications for the future of pharmaceuticals and medical devices. With the enormous potential 3D printed products have in the life sciences, there are equally as many unknowns regarding risk and liability throughout the supply chain.